Integrin α3β1–CD151 complex regulates dimerization of ErbB2 via RhoA

Oncogene

Volumn 33, Issue 21, 2014, Pages 2779-2789

  Novitskaya, V ^a   Romanska, H ^b   Kordek, R ^b   Potemski, P ^b   Kusinska R ^b   Parsons, M ^c   Odintsova, E ^a   Berditchevski, F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

breast cancer; CD151; ErbB2; integrin; tetraspanin

Indexed keywords

ANTINEOPLASTIC AGENT; CD151 ANTIGEN; CD151 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN; TRASTUZUMAB; VERY LATE ACTIVATION ANTIGEN 3; LAMININ; TETRASPANIN;

ARTICLE; BREAST TUMOR; CELL POLARITY; FEMALE; HUMAN; METABOLISM; MORTALITY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COMPLEX FORMATION; DEPHOSPHORYLATION; DIMERIZATION; EXTRACELLULAR MATRIX; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STEADY STATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD151; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL POLARITY; FEMALE; HUMANS; INTEGRIN ALPHA3BETA1; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, ERBB-2; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84901293737     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.231     Document Type: Article

References (54)

1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177–184. DOI: 10.1016/j.ceb.2008.12.010
2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16–32. DOI: 10.1038/nrclinonc.2011.177
3. Bailey TA, Luan H, Clubb RJ, Naramura M, Band V, Raja SM et al. Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinogen 2011; 10: 28. DOI: 10.4103/1477-3163.90442
4. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011; 29: 166–173. DOI: 10.1200/JCO.2009.27.7814
5. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011; 108: 3761–3766. DOI: 10.1073/pnas.1014835108
6. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC et al. Beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13: R84. DOI: 10.1186/bcr2936
7. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122: 35–43. DOI: 10.1007/s10549-009-0502-2
8. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hausler S, Ossadnik M et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 2009; 69: 8058–8066. DOI: 10.1158/0008-5472.CAN-09-0834
9. Giancotti FG. Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci 2007; 28: 506–511. DOI: 10.1016/j.tips.2007.08.004
10. Falcioni R, Antonini A, Nistico P, Di SS, Crescenzi M, Natali PG et al. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 1997; 236: 76–85. DOI: 10.1006/excr.1997.3695
11. Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ et al. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123 (Part 8): 1373–1382. DOI: 10.1242/jcs.050906
12. Huck L, Pontier SM, Zuo DM, Muller WJ. Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010; 107: 15559–15564. DOI: 10.1073/pnas.1003034107
13. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O’Rear LD, Nashabi A et al. The alphabeta integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011; 121: 226–237. DOI: 10.1172/JCI42328
14. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006; 66: 1526–1535. DOI: 10.1158/0008-5472.CAN-05-3071
15. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 2009; 69: 8620–8628. DOI: 10.1158/0008-5472.CAN-09-1591
16. Chen LL, Gabarra V, Cho S, Browning B, Cao X, Huet H et al. Functional characterization of integrin alpha6beta4 adhesion interactions using soluble integrin constructs reveals the involvement of different functional domains in the beta4 subunit. Cell Commun Adhes 2008; 15: 317–331. DOI: 10.1080/15419060802428356
17. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE et al. Disruption of laminin–integrin–CD151–focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010; 70: 2256–2263. DOI: 10.1158/0008-5472.CAN-09-4032
18. Stipp CS. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 2010; 12: e3. DOI: 10.1017/S1462399409001355
19. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000; 87: 336–342. DOI: 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3
20. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol 2004; 30: 484–489. DOI: 10.1016/j.ejso.2004.01.016
21. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD et al. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 2009; 7: 787–798. DOI: 10.1158/1541-7786.MCR-08-0574
22. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 2012; 106: 923–930. DOI: 10.1038/bjc.2012.11
23. Deng X, Li Q, Hoff J, Novak M, Yang H, Jin H et al. Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia 2012; 14: 678–689. DOI: 10.1593/neo.12922
24. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785–792. DOI: 10.1038/ncb0901-785
25. Kazarov AR, Yang X, Stipp CS, Sehgal B, Hemler ME. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J Cell Biol 2002; 158: 1299–1309. DOI: 10.1083/jcb.200204056
26. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM et al. Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem 2010; 285: 1555–1568. DOI: 10.1074/jbc.M109.057976
27. Itoh RE, Kurokawa K, Ohba Y, Yoshizaki H, Mochizuki N, Matsuda M. Activation of rac and cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. Mol Cell Biol 2002; 22: 6582–6591. DOI: 10.1128/MCB.22.18.6582-6591.2002
28. Scales TME, Jayo A, Obara B, Holt MR, Hotchin NA, Berditchevski F et al. α3β1 integrins regulate CD151 complex assembly and membrane dynamics in carcinoma cells within 3D environments. Oncogene 2013; 32: 3965–3979. DOI: 10.1038/onc.2012.415
29. Hong IK, Jeoung DI, Ha KS, Kim YM, Lee H. Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between[beta]1 integrins and small GTPases. J Biol Chem 2012; 287: 32027–32039. DOI: 10.1074/jbc.M111.314443
30. Zhang F, Michaelson JE, Moshiach S, Sachs N, Zhao W, Sun Y et al. Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. Blood 2011; 118: 4274–4284. DOI: 10.1182/blood-2011-03-339531
31. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006; 126: 489–502. DOI: 10.1016/j.cell.2006.05.047
32. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 2009; 69: 475–482. DOI: 10.1158/0008-5472.CAN-08-2649
33. Alexi X, Berditchevski F, Odintsova E. The effect of cell–ECM adhesion on signalling via the ErbB family of growth factor receptors. Biochem Soc Trans 2011; 39: 568–573. DOI: 10.1042/BST0390568
34. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315: 638–648. DOI: 10.1016/j.yexcr.2008.10.024
35. Prakash A, Janosi L, Doxastakis M. GxxxG motifs, phenylalanine, and cholesterol guide the self-association of transmembrane domains of ErbB2 receptors. Biophys J 2011; 101: 1949–1958. DOI: 10.1016/j.bpj.2011.09.017
36. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 2002; 277: 28468–28473. DOI: 10.1074/jbc.M202510200
37. Orr G, Hu D, Ozcelik S, Opresko LK, Wiley HS, Colson SD. Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. Biophys J 2005; 89: 1362–1373. DOI: 10.1529/biophysj.104.056192
38. Sharpe S, Barber KR, Grant CW. Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers. Biochemistry 2002; 41: 2341–2352. DOI: 10.1021/bi011340f
39. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T et al. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 2006; 273: 1821–1830. DOI: 10.1111/j.1742-4658.2006.05203.x
40. Nagy P, Vereb G, Sebestyen Z, Horvath G, Lockett SJ, Damjanovich S et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 2002; 115 (Part 22): 4251–4262. DOI: 10.1242/jcs.00118
41. Malaval C, Laffargue M, Barbaras R, Rolland C, Peres C, Champagne E et al. RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal 2009; 21: 120–127. DOI: 10.1016/j.cellsig.2008.09.016
42. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001; 20: 755–766. DOI: 10.1093/emboj/20.4.755
43. Banyard J, Anand-Apte B, Symons M, Zetter BR. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene 2000; 19: 580–591. DOI: 10.1038/sj.onc.1203338
44. Hopkins AM, Walsh SV, Verkade P, Boquet P, Nusrat A. Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. J Cell Sci 2003; 116 (Part 4): 725–742. DOI: 10.1242/jcs.00300
45. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011; 71: 1871–1882. DOI: 10.1158/0008-5472.CAN-10-1872
46. Baldwin G, Novitskaya V, Sadej R, Pochec E, Litynska A, Hartmann C et al. Tetraspanin cd151 regulates glycosylation of alpha3beta1 integrin. J Biol Chem 2008; 283: 35445–35454. DOI: 10.1074/jbc.M806394200
47. Berditchevski F, Chang S, Bodorova J, Hemler ME. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 1997; 272: 29174–29180. DOI: 10.1074/jbc.272.46.29174
48. Hemler ME, Ware CF, Strominger JL. Characterization of a novel differentiation antigen complex recognized by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T cells. J Immunol 1983; 131: 334–340.
49. Tachibana I, Bodorova J, Berditchevski F, Zutter MM, Hemler ME. NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem 1997; 272: 29181–29189. DOI: 10.1074/jbc.272.46.29181
50. Weitzman JB, Pasqualini R, Takada Y, Hemler ME. The function and distinctive regulation of the integrin VLA-3 in cell adhesion, spreading and homotypic cell aggregation. J Biol Chem 1993; 268: 8651–8657.
51. Novitskaya V, Romanska H, Dawoud M, Jones JL, Berditchevski F. Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ. Cancer Res 2010; 70: 4698–4708. DOI: 10.1158/0008-5472.CAN-09-4330
52. Parsons M, Messent AJ, Humphries JD, Deakin NO, Humphries MJ. Quantification of integrin receptor agonism by fluorescence lifetime imaging. J Cell Sci 2008; 121 (Part 3): 265–271. DOI: 10.1242/jcs.018440
53. Morton PE, Parsons M. Measuring FRET using time-resolved FLIM. Methods Mol Biol 2011; 769: 403–413. DOI: 10.1007/978-1-61779-207-6_27
54. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–145. DOI: 10.1200/JCO.2006.09.2775